RedHill Biopharma

RDHL

Tel-Aviv, Israel· Est. 2009

redhillbio.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

RDHL · Stock Price

USD 1.01-0.99 (-49.50%)

Market Cap: $5.2M

Historical price data

Market Cap: $5.2MPipeline: 20 drugs (8 Phase 3)Founded: 2009Employees: 51-200HQ: Tel-Aviv, Israel

Sector Ranking#362 in Small Molecule Drugs

Overview

RedHill Biopharma is a publicly traded, Israel-based company dedicated to developing and commercializing novel, primarily oral, small-molecule drugs for significant unmet medical needs. Its strategy integrates in-house R&D with strategic acquisitions to build a portfolio focused on GI diseases, infectious diseases, and oncology. A key achievement is establishing a late-stage pipeline of host-directed oral antivirals designed as broad-spectrum, mutation-resistant medical countermeasures suitable for government stockpiling.

GastroenterologyInfectious DiseaseOncology

Technology Platform

Focus on developing host-directed, oral, small-molecule therapies that target human cellular pathways exploited by pathogens, offering broad-spectrum potential and resistance to viral mutations.

Pipeline

20 drugs in pipeline8 in Phase 3

Drug	Indication	Stage
RHB-102 + Placebo Oral Tablet	Gastroenteritis	Phase 3
RHB-105 + Placebo	Dyspepsia	Phase 3
RHB-104 + Placebo	Crohn's Disease	Phase 3
RHB-105 + Active Comparator	Helicobacter Pylori Infection	Phase 3
RHB-204 + Placebo	Pulmonary Mycobacterium Avium Complex Infection	Phase 3

Funding History

Total raised:$135M

Debt$50MHCRMar 15, 2021

PIPE$25MUndisclosedMay 15, 2020

IPO$60MUndisclosedJan 15, 2016

Opportunities

Significant opportunity in government stockpiling for pandemic/biodefense via its late-stage, broad-spectrum oral antivirals.

RHB-204 addresses a high-unmet need orphan disease market with first-in-class potential.

Successful data could trigger lucrative partnerships.

Risk Factors

Extreme clinical trial dependency; failure of lead assets opaganib or RHB-107 could be existential.

Limited cash runway necessitates future dilutive financing or unfavorable partnership terms.

Intense competition in all target indications.

Competitive Landscape

Faces competition from dominant direct-acting antivirals (Pfizer, Merck) in COVID-19, but differentiates with host-directed, broad-spectrum approach. In NTM disease, competes with Insmed and other developers. Oncology indications are highly competitive with numerous established therapies.